Covalent inhibition of the lymphoid tyrosine phosphatase

ChemMedChem. 2014 Feb;9(2):296-9. doi: 10.1002/cmdc.201300404. Epub 2014 Jan 8.

Abstract

Covalent inhibitors of lymphoid tyrosine phosphatase (LYP) were identified from a screen of the NIH Molecular Libraries Small Molecules Repository (MLSMR). Both of the two lead compounds identified have phosphotyrosine-mimetic benzoic acid moieties as well as electrophilic acrylonitrile groups. Inhibition kinetics of both compounds are consistent with covalent modification of the enzyme, with nanomolar KI and reciprocal millisecond kinact values, representing the best efficiency ratios (kinact /KI ) among currently reported covalent LYP inhibitors. Covalent inhibitors can provide longer efficacy and better selectivity than more conventional noncovalent inhibitors, and these lead compounds are an important step toward the development of protein tyrosine phosphatase (PTP)-targeted covalent therapeutic compounds.

Keywords: LYP; PTP; acrylonitriles; electrophiles; irreversible inhibitors; phosphatases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Kinetics
  • Protein Tyrosine Phosphatase, Non-Receptor Type 22 / antagonists & inhibitors*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 22 / metabolism
  • Small Molecule Libraries / chemistry*
  • Small Molecule Libraries / pharmacology*
  • Structure-Activity Relationship

Substances

  • Enzyme Inhibitors
  • Small Molecule Libraries
  • Protein Tyrosine Phosphatase, Non-Receptor Type 22